EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High-sensitivity MAM to support early-stage activities during biotherapeutic development

Silvia Millán-Martín, Anna Mulligan, Lisa Füssl, Sara Carillo, Jonathan Bones

Journal of Chromatography A · 2026-05 · 1774 · 466862

DOI: 10.1016/j.chroma.2026.466862 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Chromatography A, 2026-05. Verfasst von Silvia Millán-Martín und 4 weiteren Autor:innen. Beteiligte Einrichtung: Characterisation and Comparability Laboratory, National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, …. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Antibodies, Monoclonal, Liquid Chromatography-Mass Spectrometry. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thermo Fisher Scientific Inc, Taighde Éireann - Research Ireland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During early-stage biotherapeutic development, analytical methods play an important role in candidate screening, process development, formulation screening and stability determination. However, developing sensitive and robust analytical methods is challenging in the early stages as there is often insufficient product knowledge and limited sample amount. Here we present a high-sensitivity multi-attribute method (MAM) centred on nano-flow LC-MS/MS for the characterisation of mAb-based molecules. Using NISTmAb as a reference, run-to-run variation was examined, in terms of peak area, peak width, peak asymmetry, retention time precision and mass accuracy. The ability to detect and quantify commonly observed product quality attributes (PQAs) was also evaluated for a wide range of injected digest amounts from 1 ng to 100 ng. LOD and LOQ were between 0.6 to 7.0 ng of injected protein amount (R² > 0.99), for a selection of low abundant PQAs including deamidation, oxidation, succinimide and lysine content, following regulatory considerations on the implementation of MAM in QC. The nano-flow MAM approach was then applied as an in-process test to study PQAs and impurities of a chimeric IgG1 mAb. Low amounts of samples were digested followed by high resolution nano-LC-MS/MS, Orbitrap-based mass detection, operated within a Code of Federal Regulations (CFR) Part 11 compliant data system for data acquisition and data analysis. Finally, the new peak detection (NPD) aspect of the method was also evaluated, as an in-process test for detection of low-level impurities. The results highlight the potential of nano-flow MAM for early-stage process development and its suitability for QC applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryAntibodies, MonoclonalLiquid Chromatography-Mass SpectrometryLimit of DetectionReproducibility of ResultsImmunoglobulin G

Stichwörter der Autor:innen

Critical quality attributesMonoclonal antibodyMulti-attribute methodNISTmAbNew peak detectionPeptide mappingnano-flow LC-MS

Substanzen

Antibodies, MonoclonalImmunoglobulin G

Autor:innen und Institutionen

  • Characterisation and Comparability Laboratory, National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, A94 X099, Ireland.
  • Characterisation and Comparability Laboratory, National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, A94 X099, Ireland; School of Chemical and Bioprocess Engin…

Förderung

  • Thermo Fisher Scientific Inc
  • Taighde Éireann - Research Ireland

Zitieren

APA

Millán-Martín, S., Mulligan, A., Füssl, L., Carillo, S., & Bones, J. (2026). High-sensitivity MAM to support early-stage activities during biotherapeutic development. Journal of Chromatography A, 1774, 466862. https://doi.org/10.1016/j.chroma.2026.466862

Vancouver

Millán-Martín S, Mulligan A, Füssl L, Carillo S, Bones J. High-sensitivity MAM to support early-stage activities during biotherapeutic development. Journal of Chromatography A. 2026;1774:466862. doi:10.1016/j.chroma.2026.466862

BibTeX
@article{MillnMartn2026,
  author = {Millán-Martín, Silvia and Mulligan, Anna and Füssl, Lisa and Carillo, Sara and Bones, Jonathan},
  title = {High-sensitivity MAM to support early-stage activities during biotherapeutic development},
  journal = {Journal of Chromatography A},
  year = {2026},
  volume = {1774},
  pages = {466862},
  doi = {10.1016/j.chroma.2026.466862}
}
Kostenlos starten →